Zobrazeno 1 - 10
of 2 772
pro vyhledávání: '"acute Myeloid Leukemia (AML)"'
Publikováno v:
Alexandria Journal of Medicine, Vol 60, Iss 1, Pp 282-289 (2024)
Introduction Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of immature myeloid cells. Among the genetic alterations in AML, the RUNX1- RUNX1T1 fusion, resulting from the t (8; 21) (q22; q
Externí odkaz:
https://doaj.org/article/a8afefcf9d974e1a9ddc5d5ce50dca6b
Publikováno v:
Alexandria Journal of Medicine, Vol 60, Iss 1, Pp 259-264 (2024)
Background Acute myeloid leukemia (AML) is a clonal hematopoietic stem cell malignancy characterized by the accumulation of myeloid progenitor cells with arrested differentiation, leading to the suppression of normal hematopoiesis. The disease exhibi
Externí odkaz:
https://doaj.org/article/722ae48307d1464a98a6dc83d9f7fe80
Autor:
Andrea Ghelli Luserna di Rorà, Mouna Jandoubi, Antonella Padella, Anna Ferrari, Andrea Marranci, Cristina Mazzotti, Francesco Olimpico, Martina Ghetti, Lorenzo Ledda, Maria Teresa Bochicchio, Matteo Paganelli, Michele Zanoni, Alessandro Cafaro, Chiara Servili, Sara Galimberti, Michele Gottardi, Michela Rondoni, Mauro Endri, Daniela Onofrillo, Ernesta Audisio, Giovanni Marconi, Giorgia Simonetti, Giovanni Martinelli
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-18 (2024)
Abstract Background The introduction of antibody–drug conjugates represents a significant advancement in targeted therapy of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Our study aims to investigate the role of the DNA dama
Externí odkaz:
https://doaj.org/article/1b46b4b2fe0042f6bbd4a552ab12b9e6
Autor:
Chenxu Zhu, Thomas Stiehl
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Acute myeloid leukemia (AML) is a stem cell-driven malignancy of the blood forming (hematopoietic) system. Despite of high dose chemotherapy with toxic side effects, many patients eventually relapse. The “7+3 regimen”, which consists of
Externí odkaz:
https://doaj.org/article/8f02ebadfb574c74abf0bc8a013179de
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6050-6060 (2024)
High-risk acute myeloid leukemia has been associated with a poor outcome. Hematopoietic stem cell transplantation (HSCT) represents the only curative option for eligible patients. Relapse after HSCT is a dramatic event with poor chances of survival.
Externí odkaz:
https://doaj.org/article/7d2a0582d8b74d75be61630a44c107e4
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract The tumor microenvironment (TME) plays an important role in the occurrence and progression of Acute Myeloid Leukemia (AML). Single-cell sequencing has enabled researchers to explore the correlation between TME subgroups and tumor prognosis,
Externí odkaz:
https://doaj.org/article/9e79993f16b0463cabc894570976ba2c
Publikováno v:
BMC Pediatrics, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Objective Patients who carry NUP98::NSD1 or FLT3/ITD mutations are reported to have poor prognosis. Previous studies have confidently reported that the poor outcome in younger AML patients is owning to dual NUP98::NSD1 and FLT3/ITD positivit
Externí odkaz:
https://doaj.org/article/705eaaf96dad49d9b9ff5dc7a3c1f11e
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Acute myeloid leukemia (AML) is the common blood cancer in hematopoietic system-related diseases and has a poor prognosis. Studies have shown that long non-coding RNAs (lncRNAs) are closely related to the pathogenesis of a variety of diseases, includ
Externí odkaz:
https://doaj.org/article/cd3bfd41a777415b9effef3dd756c968
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/adc434aeb1a4406d83975da122237747
Autor:
Sakditad Saowapa, Natchaya Polpichai, Manasawee Tanariyakul, Thanathip Suenghataiphorn, Narathorn Kulthamrongsri, Maireigh McCullough, Mariana Goncalves Damasceno Moreira, Pharit Siladech, Lukman Tijani
Publikováno v:
Hemato, Vol 5, Iss 2, Pp 208-219 (2024)
Background: Autoimmune disorders (ADs) are prevalent among patients with myelodysplastic syndrome (MDS), yet their impact on MDS outcomes, including overall survival (OS), mortality, and transformation to acute myeloid leukemia (AML), is not well def
Externí odkaz:
https://doaj.org/article/caf72f6cfce3483f9dc535d13360fb08